PF 5212377
Alternative Names: PF-05212377; PF-5212377; SAM-760; WYE-103760Latest Information Update: 05 Nov 2023
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Antidementias; Small molecules
- Mechanism of Action Serotonin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in France (PO, Capsule)
- 28 Oct 2014 Phase-II clinical trials in Alzheimer's disease (Adjunctive treatment) in Canada (PO)
- 23 Oct 2014 Phase-II clinical trials in Alzheimer's disease (Adjunctive treatment) in Spain (PO)